The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Treatment with romosozumab led to improvements in bone microarchitecture among postmenopausal women with osteoporosis.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...